Skip to search formSkip to main contentSkip to account menu

Rubraca

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

rucaparib
rucaparib 200 MG Oral Tablet [Rubraca]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Rucaparip (Rubraca®) induces necrosis via upregulating the expression of RIP1 and RIP3 in ovarian cancer cells.
In the current study we investigated the inhibitory effect of rucaparib (Rubraca®) on human ovarian cancer SKOV3 and A2780 cells… 
2018
2018
Submits Application to EMA to Expand Use of Rubraca ® ▼ ( rucaparib ) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer
  • 2018
  • Corpus ID: 53518531
BOULDER, Colo.-(BUSINESS WIRE) -June 4, 2018-Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory… 
2017
2017
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies.1 The National Cancer Institute estimates… 
2017
2017
NEW DRUG APPROVALS Rubraca for Ovarian Cancer
  • 2017
  • Corpus ID: 20909108
NEW DRUG APPROVALS Rubraca for Ovarian Cancer The FDA has granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) to… 
2016
2016
Rucaparib Gets FDA Approval for BRCA-Mutated Ovarian Cancer
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)